Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard ba...

Descripción completa

Detalles Bibliográficos
Autores: Mogollón, Pedro, Díaz Tejedor, Andrea, Algarín, Esperanza M., Paíno, Teresa, Garayoa, Mercedes, Ocio San Miguel, Enrique María|||0000-0002-5765-0085
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/21519
Acceso en línea:http://hdl.handle.net/10902/21519
Access Level:acceso abierto
Palabra clave:Multiple Myeloma
Resistance
Proteasome Inhibitors
Immunomodulatory Agents
Monoclonal Antibodies
Resensitization
id ES_e1ca934bbd28a6c38aa059545cddd9cf
oai_identifier_str oai:repositorio.unican.es:10902/21519
network_acronym_str ES
network_name_str España
repository_id_str
spelling Biological Background of Resistance to Current Standards of Care in Multiple MyelomaMogollón, PedroDíaz Tejedor, AndreaAlgarín, Esperanza M.Paíno, TeresaGarayoa, MercedesOcio San Miguel, Enrique María|||0000-0002-5765-0085Multiple MyelomaResistanceProteasome InhibitorsImmunomodulatory AgentsMonoclonal AntibodiesResensitizationA high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.Funding: E.M.O. was supported by an Inplant grant fromIDIVALand TP by a grant fromAECC(INVES18043PAÍN). E.M.A. and A.D.-T. received a grant from the Regional Council from Castilla y León, and P.M. from the Institute for Biomedical Research from Salamanca. This work was supported by funding from Spanish FIS (PI15/00067, PI15/02156 and PI18/01600) and FEDER, AECC (GCB120981SAN), Ramón Areces Foundation (FRA16/003); the Regional Council from Castilla y León (GRS 1604/A/17, GRS 1880/A/18 and Centro en Red de Medicina Regenerativa y Terapia Celular), and the Institute for Biomedical Research from Salamanca (IBY17/00008).MDPIUniversidad de Cantabria20192019-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttp://hdl.handle.net/10902/21519Cells . 2019 Nov 13;8(11):1432reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/215192026-06-02T12:39:31Z
dc.title.none.fl_str_mv Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
title Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
spellingShingle Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, Pedro
Multiple Myeloma
Resistance
Proteasome Inhibitors
Immunomodulatory Agents
Monoclonal Antibodies
Resensitization
title_short Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
title_full Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
title_fullStr Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
title_full_unstemmed Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
title_sort Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
dc.creator.none.fl_str_mv Mogollón, Pedro
Díaz Tejedor, Andrea
Algarín, Esperanza M.
Paíno, Teresa
Garayoa, Mercedes
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
author Mogollón, Pedro
author_facet Mogollón, Pedro
Díaz Tejedor, Andrea
Algarín, Esperanza M.
Paíno, Teresa
Garayoa, Mercedes
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
author_role author
author2 Díaz Tejedor, Andrea
Algarín, Esperanza M.
Paíno, Teresa
Garayoa, Mercedes
Ocio San Miguel, Enrique María|||0000-0002-5765-0085
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv Multiple Myeloma
Resistance
Proteasome Inhibitors
Immunomodulatory Agents
Monoclonal Antibodies
Resensitization
topic Multiple Myeloma
Resistance
Proteasome Inhibitors
Immunomodulatory Agents
Monoclonal Antibodies
Resensitization
description A high priority problem in multiple myeloma (MM) management is the development of resistance to administered therapies, with most myeloma patients facing successively shorter periods of response and relapse. Herewith, we review the current knowledge on the mechanisms of resistance to the standard backbones in MM treatment: proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies (mAbs). In some cases, strategies to overcome resistance have been discerned, and an effort should be made to evaluate whether resensitization to these agents is feasible in the clinical setting. Additionally, at a time in which we are moving towards precision medicine in MM, it is equally important to identify reliable and accurate biomarkers of sensitivity/refractoriness to these main therapeutic agents with the goal of having more efficacious treatments and, if possible, prevent the development of relapse.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10902/21519
url http://hdl.handle.net/10902/21519
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Cells . 2019 Nov 13;8(11):1432
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422325562081280
score 15,301603

Similares en LA Referencia